Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $0.70 per diluted share, a significant improvement from a net loss of $0.83 per diluted share in Q1 2024 [5] - Interest income increased by $23.6 million to $22 million in Q1 2025, compared to a net loss of $1.6 million in Q1 2024, driven by higher rates [6] - Earnings available for distribution rose to $0.41 per diluted common share in Q1 2025 from negative $0.46 per diluted share in the same period of 2024 [6] - Cash available for distribution was $0.45 per diluted common share in Q1 2025, down from $0.60 per diluted common share in Q1 2024 [6] - Book value per share increased by 1.47% from Q4 2024 to $17.22 per diluted common share [7] Business Line Data and Key Metrics Changes - The portfolio consists of 85 investments with a total outstanding balance of $1.2 billion, allocated as follows: 49.4% multifamily, 31.9% life sciences, 15.6% single-family rental, 1.6% storage, 0.9% specialty manufacturing, and 0.6% marina [9] - The investment allocation includes 28.4% CMBS BPs, 24.7% mezzanine loans, 19% preferred equity investments, 12.9% revolving credit facilities, 10.4% senior loans, 4.2% IO strips, and 0.3% promissory notes [9] Market Data and Key Metrics Changes - The company reported strong demand in the residential sector, with over 138,000 units absorbed in Q1 2025, marking a record first quarter performance [14] - Sunbelt markets captured a majority of the top 10 markets for absorption in Q1 2025, indicating robust demand in these regions [14] - The life sciences sector is experiencing challenges due to tariff and NIH funding uncertainties, but there are positive developments in specific projects, such as the Alewife project [12][13] Company Strategy and Development Direction - The company remains focused on the residential sector, anticipating increased rental growth and transaction volume in the coming quarters [15] - There is an emphasis on self-storage development opportunities, with expected yields ranging from 8.1% to 8.5% [15][16] - The company plans to actively market several equity investments to generate approximately $75 million of new equity for reinvestment into income-producing assets [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the residential sector, believing it has bottomed out and is poised for growth [14][22] - The life sciences sector is expected to see a resolution of current uncertainties by mid-2025, which could lead to increased capital allocation decisions [12][21] - Overall, the company is confident in its portfolio's performance and sees opportunities in the multifamily and self-storage sectors [16] Other Important Information - The company paid a regular dividend of $0.50 per share in Q1 2025 and has declared a similar dividend for Q2 2025 [7] - The debt to equity ratio stands at 1.33 times, with a weighted average cost of debt at 6% [10] Q&A Session Summary Question: Can you comment on the credit side and notable credit loss provision? - Management indicated that a weighted average base case and downside scenario for CECL reserve was implemented, contributing to the credit loss provision [19] - A proactive reserve was applied to a private preferred asset, leading to the uptick in credit loss provision [20] Question: What is the leasing momentum for the life science project? - The project is expected to be two-thirds leased, resulting in a debt yield of almost 11% from two tenants [25] Question: What are the future investment plans? - The company plans to focus on residential space, preferreds, and ramping up CMBS B pieces, with a particular interest in short-term stretch senior opportunities [31]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $0.70 per diluted share, a significant improvement from a net loss of $0.83 per diluted share in Q1 2024 [4] - Interest income increased by $23.6 million to $22 million in Q1 2025, compared to a net loss of $1.6 million in Q1 2024, driven by higher rates [5] - Earnings available for distribution rose to $0.41 per diluted common share in Q1 2025 from negative $0.46 per diluted share in the same period of 2024 [5] - Cash available for distribution was $0.45 per diluted common share in Q1 2025, down from $0.60 per diluted common share in Q1 2024 [5] - Book value per share increased by 1.47% from Q4 2024 to $17.22 per diluted common share, primarily due to unrealized gains on preferred stock investments [6] Business Line Data and Key Metrics Changes - The portfolio consists of 85 investments with a total outstanding balance of $1.2 billion, allocated as follows: 49.4% multifamily, 31.9% life sciences, 15.6% single-family rental, 1.6% storage, 0.9% specialty manufacturing, and 0.6% marina [8] - The assets collateralizing investments are 75.2% stabilized with a loan-to-value ratio of 58.7% and a weighted average debt service coverage ratio (DSCR) of 1.46 times [8] Market Data and Key Metrics Changes - In the life sciences sector, lab leasing remains challenging due to tariff and NIH funding uncertainties, but there are signs of recovery with positive leasing momentum in specific projects [11][12] - The residential sector saw strong demand with over 138,000 units absorbed in Q1 2025, indicating a robust rental market [13] - The company has observed positive new lease growth across 40% of its rental portfolio, up from just 5% in Q4 2024 [14] Company Strategy and Development Direction - The company aims to focus on the residential sector and is actively pursuing opportunities in self-storage development, with expected yields between 8.1% to 8.5% [14][15] - The strategy includes underwriting shorter-term senior loans to stabilize assets and facilitate lease-up in the residential front [30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for the residential sector over the next two to three years, despite temporary challenges in the life sciences sector [21] - The company remains active in the market and anticipates continued growth in key verticals [16] Other Important Information - The company paid a regular dividend of $0.50 per share in Q1 2025 and has declared the same for Q2 2025, with a coverage ratio of 0.9 times based on cash available for distribution [6] Q&A Session Summary Question: Can you comment on the credit side and notable credit loss provision? - Management indicated that a weighted average base case and downside scenario for CECL reserve was implemented, contributing to the uptick in credit loss provision [18] Question: What is the leasing momentum for the life science project? - The project is expected to be two-thirds leased, resulting in a debt yield of nearly 11% across two tenants [23] Question: What are the future investment plans? - The company plans to focus on residential space, participating in K deals with Freddie, and underwriting opportunities in the multifamily sector [30]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $0.70 per diluted share, a significant improvement from a net loss of $0.83 per diluted share in Q1 2024 [5] - Interest income increased by $23.6 million to $22 million in Q1 2025, compared to a net loss of $1.6 million in Q1 2024, driven by higher rates [6] - Earnings available for distribution rose to $0.41 per diluted common share in Q1 2025 from negative $0.46 per diluted share in the same period of 2024 [6] - Cash available for distribution was $0.45 per diluted common share in Q1 2025, down from $0.60 per diluted common share in Q1 2024 [6] - Book value per share increased by 1.47% from Q4 2024 to $17.22 per diluted common share, primarily due to unrealized gains on preferred stock investments [7] Business Line Data and Key Metrics Changes - The portfolio consists of 85 investments with a total outstanding balance of $1.2 billion, allocated as follows: 49.4% multifamily, 31.9% life sciences, 15.6% single-family rental, 1.6% storage, 0.9% specialty manufacturing, and 0.6% marina [8] - The assets collateralizing investments are 75.2% stabilized with a loan-to-value ratio of 58.7% and a weighted average debt service coverage ratio (DSCR) of 1.46 times [9] Market Data and Key Metrics Changes - In the life sciences sector, lab leasing remains challenging due to tariff and NIH funding uncertainties, but there are positive developments in specific projects like the Alewife project, which is negotiating leases for two-thirds of the space [12][13] - The residential sector saw strong demand with over 138,000 units absorbed in Q1 2025, indicating a robust rental market despite affordability challenges [14] - The company has observed positive new lease growth across 40% of its rental portfolio, up from just 5% in Q4 2024 [15] Company Strategy and Development Direction - The company aims to focus on the residential sector and is actively pursuing self-storage development opportunities, expecting yields between 8.1% to 8.5% [15][16] - There is a strategic emphasis on underwriting shorter-term senior opportunities to stabilize assets and facilitate lease-up in the residential front [31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the residential sector's performance over the next two to three years, despite short-term macroeconomic uncertainties [22] - The company remains active in its key verticals and anticipates continued growth in the coming quarters [17] Other Important Information - The company paid a regular dividend of $0.50 per share in Q1 2025 and has declared the same for Q2 2025, with the dividend being 0.9 times covered by cash available for distribution [7] Q&A Session Summary Question: Can you comment on the credit side and notable credit loss provision? - Management indicated that a weighted average base case and downside scenario for CECL reserve was implemented, along with a proactive reserve for a private preferred asset [19][20] Question: What percentage leased will the Alewife project be? - The project is expected to be two-thirds leased, resulting in a debt yield of nearly 11% from those leases [24] Question: What are the interesting opportunities in the current environment? - Management plans to focus on residential space, preferreds, and ramping up CMBS B pieces, particularly in shorter-term stretch senior opportunities [31]

Core Viewpoint - NexPoint (NREF) reported quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.46 per share, compared to a loss of $0.46 per share a year ago, indicating an earnings surprise of -10.87% [1] Group 1: Earnings Performance - Over the last four quarters, NexPoint has surpassed consensus EPS estimates three times [2] - The company posted revenues of $11.51 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 19.39%, compared to year-ago revenues of -$12.81 million [2] - The current consensus EPS estimate for the coming quarter is $0.50 on revenues of $10.17 million, and for the current fiscal year, it is $2 on revenues of $40.55 million [7] Group 2: Stock Performance and Outlook - NexPoint shares have declined approximately 6.8% since the beginning of the year, while the S&P 500 has decreased by 5.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] - The estimate revisions trend for NexPoint is mixed, and changes in earnings expectations may occur following the recent earnings report [6] Group 3: Industry Context - The REIT and Equity Trust industry, to which NexPoint belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Highlights - Net income attributable to common stockholders in 1Q 2025 was $165 million, or $070 per diluted common share[14] - Cash Available for Distribution (CAD) in 1Q 2025 was $045 per diluted common share[15] - Book Value per diluted common share increased by 15% to $1722[24] - A dividend of $050 per common share was paid for 1Q 2025[13] Portfolio Composition - The total portfolio principal was $12 billion[15] - The portfolio is composed of 85 investments[15] - The weighted average Loan-to-Value (LTV) of the portfolio is 587%[40] - The weighted average Debt Service Coverage Ratio (DSCR) of the portfolio is 146x[40] Capitalization - The debt to equity ratio was 133x as of March 31, 2025[17] - $447 million of Series B Preferred stock was raised by selling 18 million shares[17] - Outstanding Repo Financing equates to 754% advance rate on CMBS B-Piece and IO Strips Portfolio[18]

[Financial Performance and Outlook](index=1&type=section&id=Financial%20Performance%20and%20Outlook) This section details NexPoint Real Estate Finance's Q1 2025 financial performance, provides Q2 2025 guidance, and reconciles non-GAAP financial measures [First Quarter 2025 Financial Results](index=1&type=section&id=First%20Quarter%202025%20Financial%20Results) For the first quarter of 2025, NexPoint Real Estate Finance, Inc. (NREF) reported strong and resilient earnings, with a net income of $16.5 million ($0.70 per diluted share) and cash available for distribution (CAD) of $10.5 million ($0.45 per diluted common share). The company maintained a total portfolio of $1.2 billion and actively allocated capital through new investments, including a $55.0 million preferred stock purchase Q1 2025 Key Financial Metrics | Metric | Value | Per Diluted Share | | :--- | :--- | :--- | | Net Income Attributable to Common Stockholders | $16.5 million | $0.70 | | Cash Available for Distribution (CAD) | $10.5 million | $0.45 | - Management commented on the company's proactive stance in a challenging credit market, capitalizing on opportunities as traditional lenders face credit challenges[3](index=3&type=chunk) Portfolio Overview as of March 31, 2025 | Metric | Value | | :--- | :--- | | Total Portfolio Size | $1.2 billion | | Number of Investments | 85 | | Weighted-Average Loan to Value (LTV) | 58.7% | | Weighted-Average Debt Service Coverage Ratio (DSCR) | 1.46x | - The investment portfolio is primarily concentrated in multifamily (**49.4%**) and life sciences (**31.9%**), with a smaller allocation to single-family rental (**15.6%**)[7](index=7&type=chunk) - During the first quarter, NREF purchased **$55.0 million** of Preferred Stock and funded **$20.8 million** on a loan with a coupon of SOFR + 900 bps[7](index=7&type=chunk) [Second Quarter 2025 Guidance](index=2&type=section&id=Second%20Quarter%202025%20Guidance) NREF provided guidance for the second quarter of 2025, projecting Earnings Available for Distribution (EAD) of $0.43 per diluted common share and Cash Available for Distribution (CAD) of $0.48 per diluted common share at the midpoint. This guidance anticipates net income attributable to common stockholders to be between $7.6 million and $9.8 million Q2 2025 Guidance per Diluted Common Share (Midpoint) | Metric | Midpoint Value | | :--- | :--- | | Earnings Available for Distribution (EAD) | $0.43 | | Cash Available for Distribution (CAD) | $0.48 | Q2 2025 Earnings Available for Distribution (EAD) Guidance (in thousands, except per share amounts) | Metric | Low | Mid | High | | :--- | :--- | :--- | :--- | | Net income attributable to common stockholders | $7,557 | $8,771 | $9,833 | | EAD | $9,109 | $10,323 | $11,385 | | EAD per diluted common share | $0.38 | $0.43 | $0.48 | Q2 2025 Cash Available for Distribution (CAD) Guidance (in thousands, except per share amounts) | Metric | Low | Mid | High | | :--- | :--- | :--- | :--- | | CAD | $10,364 | $11,578 | $12,640 | | CAD per diluted common share | $0.43 | $0.48 | $0.53 | [Reconciliations of Non-GAAP Financial Measures](index=4&type=section&id=Reconciliations%20of%20Non-GAAP%20Financial%20Measures) The company provides a detailed reconciliation of its non-GAAP metrics, EAD and CAD, to the nearest GAAP measure, net income. For Q1 2025, GAAP net income of $16.5 million was adjusted for items like unrealized gains and stock-based compensation to arrive at an EAD of $9.7 million and a CAD of $10.5 million. This contrasts sharply with Q1 2024, which saw a GAAP net loss of $14.3 million Reconciliation of Net Income to EAD and CAD (in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | **Net income (loss) attributable to common stockholders** | **$16,518** | **($14,286)** | | Adjustments (Unrealized gains/losses, etc.) | ($6,844) | $3,729 | | **EAD** | **$9,674** | **($11,451)** | | Adjustments (Amortization, Depreciation, etc.) | $813 | $26,324 | | **CAD** | **$10,487** | **$14,873** | Per Share Metrics Comparison | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | EAD per diluted common share | $0.41 | ($0.46) | | CAD per diluted common share | $0.45 | $0.60 | - Beginning in Q2 2024, EAD and CAD per share calculations are based on an adjusted weighted average share count that excludes the potential dilutive effect of Series B Preferred Stock redemptions[14](index=14&type=chunk) [Corporate Information and Disclosures](index=3&type=section&id=Corporate%20Information%20and%20Disclosures) This section provides details on the Q1 2025 earnings conference call, company overview, and definitions of non-GAAP financial measures [Conference Call Information](index=3&type=section&id=Conference%20Call%20Information) The company scheduled a conference call for Thursday, May 01, 2025, at 11:00 a.m. ET to discuss the first quarter 2025 financial results. Access details were provided for live participation via phone and webcast, as well as for a replay available until May 15, 2025 - A conference call to discuss Q1 2025 results was scheduled for May 01, 2025, at 11:00 a.m. ET[10](index=10&type=chunk) - The call can be accessed live by dialing **888-660-4430** (Conference ID **6891136**) or via webcast on the company's website. A replay is also available[11](index=11&type=chunk)[12](index=12&type=chunk) [About the Company and Disclosures](index=5&type=section&id=About%20the%20Company%20and%20Disclosures) NexPoint Real Estate Finance, Inc. is a publicly traded REIT focused on originating and investing in various real estate debt and equity instruments. The report includes standard forward-looking statement disclaimers and provides detailed definitions for its non-GAAP financial measures, including Earnings Available for Distribution (EAD), Cash Available for Distribution (CAD), and adjusted weighted average common shares, explaining their calculation and utility for investors - NREF is a publicly traded REIT (NYSE: **NREF**) that primarily originates, structures, and invests in first-lien mortgage loans, mezzanine loans, preferred equity, and various CMBS securities[15](index=15&type=chunk) - The press release contains forward-looking statements regarding Q2 2025 guidance and business strategy, which are subject to risks and uncertainties detailed in SEC filings[16](index=16&type=chunk) - **EAD** is a non-GAAP measure used to evaluate performance and long-term ability to pay distributions. It adjusts GAAP net income for non-cash items like unrealized gains/losses and stock-based compensation[18](index=18&type=chunk) - **CAD** is calculated by adjusting EAD for certain non-cash items like amortization of premiums and depreciation to better reflect the current ability to pay distributions[19](index=19&type=chunk)

Core Viewpoint - NexPoint Real Estate Finance, Inc. (NREF) reported strong financial results for Q1 2025, demonstrating resilience in earnings amid challenging credit market conditions [1][2]. Financial Performance - NREF reported net income attributable to common stockholders of $16.5 million, or $0.70 per diluted share, for the three months ended March 31, 2025 [1]. - Cash available for distribution was $10.5 million, or $0.45 per diluted common share, for the same period [1]. - The company anticipates second quarter 2025 earnings available for distribution (EAD) per diluted common share guidance at $0.435 at the midpoint [8]. Investment Portfolio - NREF's total portfolio is valued at $1.2 billion, consisting of 85 investments across various sectors including single-family rental (15.6%), multifamily (49.4%), and life sciences (31.9%) [9]. - The weighted-average loan to value (LTV) ratio is 58.7%, with a debt service coverage ratio (DSCR) of 1.46x [9]. Future Outlook - The company remains proactive in capital allocation, aiming to capitalize on market opportunities despite traditional lenders facing credit challenges [2]. - NREF has provided guidance for Q2 2025, estimating net income attributable to common stockholders to be between $7.6 million and $9.8 million [7].

Core Viewpoint - Redwood Trust reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.17 per share, but showing an improvement from $0.08 per share a year ago, indicating a -17.65% earnings surprise [1] - The company posted revenues of $27.9 million for the quarter, missing the consensus estimate by 10.89%, compared to $24 million in the same quarter last year [2] Earnings Performance - Over the last four quarters, Redwood Trust has surpassed consensus EPS estimates two times [2] - The company had an earnings surprise of -18.75% in the previous quarter, where it was expected to post earnings of $0.16 per share but delivered $0.13 [1] Stock Performance - Redwood Trust shares have declined approximately 4.8% since the beginning of the year, while the S&P 500 has seen a decline of 5.5% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates for the upcoming quarter at $0.20 on revenues of $30.55 million, and $0.82 on revenues of $126.96 million for the current fiscal year [7] - The estimate revisions trend for Redwood Trust is currently favorable, resulting in a Zacks Rank 1 (Strong Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The REIT and Equity Trust industry, to which Redwood Trust belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [8]

Financial Data and Key Metrics Changes - For Q4 2024, the company reported net income of $0.43 per diluted share, down from $0.73 per diluted share in Q4 2023, primarily due to unrealized losses on common stock investments and changes in net assets on CMBS VIEs [10] - Interest income decreased by $15.4 million to $32.3 million in Q4 2024 from $47.7 million in Q4 2023 [10] - Earnings available for distribution were $0.83 per diluted common share in Q4, compared to $0.44 per diluted common share in the same period of 2023 [11] - Cash available for distribution was $0.47 per diluted common share in Q4, down from $0.51 per diluted common share in Q4 2023 [12] - For the full year 2024, net income was $1.02 per diluted share, up from $0.60 per diluted share in 2023 [14] Business Line Data and Key Metrics Changes - The portfolio consists of 83 investments with an outstanding balance of $1.1 billion, allocated across various sectors including 15.5% single-family rental, 49.7% multifamily, and 31% life sciences [16] - The collateral on the portfolio is 76.5% stabilized with a loan-to-value ratio of 59.2% and a weighted average debt service coverage ratio of 1.32 times [18] Market Data and Key Metrics Changes - Multifamily fundamentals are improving, with Q4 starts at 37,000 units, the lowest since Q4 2011, indicating a potential inflection point as supply wanes [21] - The company is actively underwriting $300 million of opportunities in life sciences, particularly in infrastructure and pharmaceutical manufacturing [24] Company Strategy and Development Direction - The company aims to capitalize on growth opportunities in multifamily and life sciences sectors, with expectations for new lease growth to turn positive in the second half of the year [22][23] - The company is exploring multiple avenues for funding growth, including A-note warehouses and bond-rated deals [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, citing a strong credit profile and growth potential in the multifamily and life sciences sectors [20] - The company is confident in its ability to navigate challenges in the commercial real estate sector and is prepared to take advantage of favorable market conditions [25] Other Important Information - The company paid a regular dividend of $0.50 per share in Q4 and has declared a dividend of $0.50 per share for Q1 2025 [12] - The weighted average cost of debt is 6% with a weighted average maturity of 1.4 years [18] Q&A Session Summary Question: Can you talk about the returns on new investments and how they compare to other opportunities? - Management indicated that Freddie K deals are expected to yield 8% to 9%, with potential returns in the low to mid-teens when leveraging [32] Question: Can you provide an update on life science investments and key metrics? - Management highlighted a $220 million commitment in Massachusetts, with a loan-to-cost attachment point of approximately 25% and a stabilized debt yield of over 30% [35] Question: What is the status of loan performance and any delinquent loans? - Management noted a few watch list loans but emphasized overall strong portfolio performance with minimal delinquency [40][60]